Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...

The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

On the political front, Robert F. Kennedy Jr. will become the next HHS secretary after he attained a majority of Senate votes ...

Novartis will buy Anthos Therapeutics, a Boston-based biotech focused on cardiac conditions, for an up front payment of $925 million. Anthos was founded in 2019 by Novartis and the private equity ...

as well as Anthos Therapeutics with abelacimab, an injectable Factor XI/XIa-targeting antibody that generated encouraging results in a phase 2b trial earlier this year. Milvexian is in three late ...

In 2021, Calliditas Therapeutics’ corticosteroid-based Tarpeyo ... Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab ...

The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...